Skip to content
Markets News
Global1 min read

EU Clears Daraxonrasib for Metastatic Pancreatic Cancer

Makkler Newsroom
November 17, 2026 · Based on reporting by Dünya, finanzen.net
Photo: Ragesoss / Wikimedia Commons · CC BY-SA 4.0

The authorization covers adults who have received at least one prior treatment, while a joint review of clinical benefit remains unfinished.

Key takeaways

  • The European Commission authorized Daraxonrasib for metastatic pancreatic cancer.
  • A joint assessment of the drug’s clinical benefits is still underway.

The European Commission has authorized Daraxonrasib for adults with metastatic pancreatic cancer who have received at least one previous treatment. The drug is intended as an option for patients whose current treatment choices are inadequate.

The European Medicines Agency completed its scientific review through an accelerated, rolling assessment and issued a positive opinion. The Commission said safety, quality and efficacy standards were maintained during the process.

A joint review of the drug’s clinical benefits is not yet complete. The Commission said a report is targeted for December, as work continues to support patient access across Europe.

Topics
DaraxonrasibEuropean Commission
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.